Jacobs Levy Equity Management
TNYA icon

Jacobs Levy Equity Management’s Tenaya Therapeutics TNYA Stock Holding History

Jacobs Levy Equity Management’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-75,927
Closed -$54K – 1066
2025
Q4 		$54K Buy
+75,927
New +$103K ﹤0.01% 914
2024
Q4 		– Sell
-337,265
Closed -$651K – 1041
2024
Q3 		$651K Buy
337,265
+226,466
+204% +$639K ﹤0.01% 799
2024
Q2 		$343K Sell
110,799
-57,766
-34% -$239K ﹤0.01% 879
2024
Q1 		$882K Buy
168,565
+80,212
+91% +$384K ﹤0.01% 738
2023
Q4 		$286K Buy
+88,353
New +$191K ﹤0.01% 893
2023
Q1 		– Sell
-97,631
Closed -$196K – 1059
2022
Q4 		$196K Sell
97,631
-159,004
-62% -$388K ﹤0.01% 911
2022
Q3 		$744K Buy
+256,635
New +$1.2M 0.01% 769

Other funds holding TNYA

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management's TNYA Position: Q1 2026 in Review

Jacobs Levy Equity Management sold out of Tenaya Therapeutics (TNYA) in Q1 2026, closing a stake of 75,927 shares — an estimated $54K sold.

Jacobs Levy Equity Management first reported a position in TNYA in Q3 2022 and held it in 7 quarters. The position peaked at $882K in Q1 2024. 103 funds tracked by Wall St. Rank hold TNYA as of Q1 2026.

  • Jacobs Levy Equity Management reported no remaining Tenaya Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 75,927 Tenaya Therapeutics shares in Q1 2026, an estimated $54K.
  • Jacobs Levy Equity Management first reported a position in Tenaya Therapeutics in Q3 2022 and held it in 7 quarters.
  • Jacobs Levy Equity Management's Tenaya Therapeutics position peaked at $882K in Q1 2024.
  • 103 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.